Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has successfully registered a share capital increase following the conversion of convertible bonds by Atlas Special Opportunities, LLC. This development strengthens Circio’s financial position to continue its pioneering work in RNA therapeutics and cancer vaccine research, indicating potential growth and advancements in their industry-leading technologies.
More about Targovax ASA
Circio Holding ASA is a biotechnology company that focuses on developing innovative circular RNA gene therapies and immunotherapy medicines. Utilizing their proprietary circVec technology, Circio aims to revolutionize DNA and virus-based therapeutics with enhanced and durable protein expression. The company also explores cancer vaccines through its subsidiary Circio AB, leveraging collaborations and grants for clinical trials in cancer treatment.
YTD Price Performance: 0.04%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: NOK49.95M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.
